Background: Cancer-testis antigens (CTAs) are suitable targets for cancer-specific immunotherapy. The aim of the study is to investigate the expression of CTAs in intrahepatic cholagiocarcinoma (IHCC) and evaluate their potential therapeutic values.
Methods: Eighty-nine IHCC patients were retrospectively assessed for their expression of CTAs and HLA Class I by immunohistochemistry using the following antibodies: MA454 recognizing MAGE-A1, 57B recognizing multiple MAGE-A (MAGE-A3/A4), E978 recognizing NY-ESO-1, and EMR8-5 recognizing HLA class I. The clinicopathological and prognostic significance of individual CTA markers and their combination were further evaluated.
Results: The expression rates of MAGE-A1, MAGE-A3/4 and NY-ESO-1 were 29.2%, 27.0% and 22.5%, respectively. The concomitant expression of CTAs and HLA class I antigen was observed in 33.7% of the IHCC tumors. We found that positive MAGE-3/4 expression correlated with larger tumor size (≥ 5 cm), tumor recurrence and poor prognosis. Moreover, we identified 52 cases (58.4%) of IHCC patients with at least one CTA marker expression, and this subgroup displayed a higher frequency of larger tumor size and a shorter survival than the other cases. Furthermore, expression of at least one CTA marker was also an independent prognostic factor in patients with IHCC.
Conclusion: Our data suggest that specific immunotherapy targeted CTAs might be a novel treatment option for IHCC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023685 | PMC |
| http://dx.doi.org/10.1186/1756-9966-30-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201.
EBioMedicine
January 2025
State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, 100021, China. Electronic address:
Background: Small cell lung cancer (SCLC) represents a highly aggressive neuroendocrine tumour with a dismal prognosis. Currently, the identification of a specific tumour antigen that can facilitate immune-based therapies for SCLC remains elusive.
Methods: We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyse cancer/testis antigens (CTAs) in SCLC cell lines and human tumour specimens.
Mining and Characterization of Amylosucrase from for Synthesis of α-Arbutin Using Sucrose.
Int J Mol Sci
December 2024
College of Life Sciences, Yangtze University, 1 South-Loop Road, Jingzhou 434025, China.
α-Arbutin is the fourth generation whitening factor in the field of cosmetics, which can block the synthesis of melanin in epidermal cells and has the advantages of good stability and less toxic side effects. Moreover, α-arbutin has potential application value in food, medicine, and other fields. However, the extraction yield from plant tissues is relatively low, which restricts its application value.
View Article and Find Full Text PDFUnveiling the significance of cancer-testis antigens and their implications for immunotherapy in glioma.
Discov Oncol
October 2024
Department of Neurosurgery, the First Affiliated Hospital of Hainan Medical University (Hainan Academy of Medical Sciences), Haikou, China.
Article Synopsis
- Gliomas have a poor prognosis due to their unique characteristics and the lack of effective treatments, making innovative therapeutic approaches necessary.
- Immunotherapy is gaining traction in cancer treatment, but current trials show limited success in improving glioma outcomes, particularly highlighting the potential of cancer-testis antigens (CTAs) as promising targets.
- CTAs are expressed in gliomas and are linked to prognosis and immune response; research shows they can be effective targets for immunotherapy, with IL13RA2 being a notable example in ongoing clinical trials.
Therapeutic options for synovial sarcoma (SyS) have not evolved for several decades and the efficacy of second-line treatments is very limited. The expression of a large family of proteins known as cancer testis antigens (CTAs) in SyS has spurred the development of targeted T-cell therapies currently in clinical trials, such as those aimed at melanoma-associated antigen (MAGE)-A4 and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), which have shown promising clinical efficacy. Extensive knowledge of the prevalence of expression and coexpression of CTAs is critical to design T-cell therapies with optimal coverage of the patient population.
View Article and Find Full Text PDFImplementing Triage-Bot: Supporting the Current Practice for Triage Nurses.
Surg Technol Int
July 2024
Queen's School of Computing, Queen's University, Kingston, Ontario, Canada.
In Canada, emergency departments (ED) have 15.1 million unscheduled visits every year; this has been suggested to indicate that patients rely on ED to address the gaps experienced by 6.5 million Canadians who lack a primary care provider.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!